- ￥600 - 3200
- 上海莼试
- CS-01Y64720
- 国产
- 2025年07月13日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
45
- 英文名：
Hydroxy Itraconazole (Itraconazole metabolite Hydroxy Itraco
- CAS号：
112559-91-8
- 供应商：
上海莼试
- 保存条件：
Store at -20°C
- 规格：
10mM*1mLinDMSO 1mg 5mg 10mg
分子式:C35H38Cl2N8O5
分子量:721.63
溶解度:DMSO: 100 mg/mL (138.58 mM); H2O: < 0.1 mg/mL (insoluble)
储存条件:Store at -20°C
General tips:For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition:Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
Hydroxy Itraconazole is an active metabolite of Itraconazole (ITZ), which is a triazole antifungal agent.Hydroxy Itraconazole (OH-ITZ) is an active metabolite of Itraconazole (ITZ). Although Hydroxy Itraconazole is also reported to have antifungal activity in vitro, its pharmacokinetics in humans has been studied less than that of ITZ. ITZ and Hydroxy Itraconazole have a triazole ring and inhibit CYP3A. Their half-lives can be extended by 26-60% with repeated administration compared to single administration[1].The plasma concentration of Hydroxy Itraconazole is weakly dependent on the dose of ITZ, most likely because the process that forms Hydroxy Itraconazole is saturated. Serum albumin and GFR may alter the pharmacokinetics of ITZ and Hydroxy Itraconazole. Antifungal activity should be discussed while taking into account not only the plasma concentration of ITZ but also that of Hydroxy Itraconazole. However, the pharmacokinetics of Hydroxy Itraconazole is similar to that of ITZ in immunocompromised patients taking an oral solution of ITZ. Since the plasma concentrations of ITZ and Hydroxy Itraconazole are closely correlated, determining the plasma concentration of either should be sufficient from a clinical point of view[1].[1]. Mino Y, et al. Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. Clin Chim Acta. 2013 Jan 16;415:128-32.
商品属性：
| 货号 | CS-01Y64720 | 规格 | 10mM*1mLinDMSO 1mg 5mg 10mg |
| CAS号 | 112559-91-8 | 分子量 | 721.63 |
| 含量 | >98.00% | 别名 | N/A |
| 分子式 | C35H38Cl2N8O5 | 化学名 | N/A |
| 产地 | 国产 | 用途 | 仅供科研研究实验 |
抗逆滴加序列
每次向板内滴加抗原时，移液器滴头要与平面45度悬空，不要触碰到孔内的液体，由后向前依次滴加(即浓度由低往高滴加)。
抗感染反应期
抗原抗体在室温20~25℃下，必须反应30min以上，若环境温度低于室温，可将微量反应板置于恒温培养箱中，使二者充分反应。
旅游温度
磷酸盐缓冲液的pH值要在高压灭菌后进行滴定，往往在高压后pH值会有所改变，所以高压后再调一次pH值更为准确。磷酸盐缓冲液一经使用保存期不要超过3周。当pH<5.8时，红细胞会产生自凝现象;当pH>7.8时，图形洗脱加快，易造成肉眼观察产生误差;p H=7.2时，红细胞沉降最充分，图形最清晰。
当滴注 1%红细胞悬液时，应经常摇晃红细胞悬液，使红细胞均匀地分布在磷酸缓冲液中，以防止红细胞下降。
反应时间及温度
加入鸡红血球之后，反应板在室温(20~25℃)静置30~40min，对照孔血球下沉于孔底，即可判定结果。若室温达不到实验要求，需相应调整反应时间。当环境温度低于4℃时，红细胞发生自凝;高于37℃时，会发生反应物分离和红细胞溶血。
公司正在出售的产品：
| TATU | Z-Hyp(tBu)-Ome |
| Fmoc-D-Asp-OH | 人骨桥素ELISA试剂盒 |
| Z-Arg(Mtr)-OH.CHA | 人骨特异性碱性磷酸酶BELISA试剂盒 |
| Fmoc-Asparaginol | 人骨涎蛋白ELISA试剂盒 |
| Fmoc-Lys(Me3)-OH | 人骨退化特异标志物ELISA试剂盒 |
| Fmoc-Gln(Trt)-Wang resin | 人过氧化还原酶1ELISA试剂盒 |
| Z-His(Dnp)-OH | 人过氧化还原酶4ELISA试剂盒 |
| Boc-Valinol | 人过氧化氢酶ELISA试剂盒 |
| Boc-DL-Ala-OH | 人骨碱性磷酸酶ELISA试剂盒 |
| H-D-Thr-OMe.HCl | 人骨钙素ELISA试剂盒 |
| H-Asp-OBzl.HCl | 人骨成型蛋白7ELISA试剂盒 |
| Boc-Arg(Mts)-OH.CHA | 人骨成型蛋白4ELISA试剂盒 |
| H-Met-OH | Hydroxy Itraconazole (Itraconazole metabolite Hydroxy Itraco人骨成型蛋白2ELISA试剂盒 |
| (-)-G-Lactone | 人骨保护素ELISA试剂盒 |
| 人CD40配ELISA试剂盒 | 人谷氧还蛋白2ELISA试剂盒 |
1.本蛋白酶抑制剂混合物为100×的储存液，使用时按照1:100的比例加入到裂解液中(例如，1ml裂解液中加入10μl蛋白酶抑制剂混合物)，混匀后即可使用。根据需要，0.5M的EDTA也按照1:100的比例加入到裂解液中（如用于检测金属蛋白酶活性，则不宜添加EDTA）。含有蛋白酶抑制剂混合物的裂解液宜现用现配，不宜配制后冻存待后续使用。
2. 待所需的抑制剂添加完毕混匀后，就可以开始进行哺乳动物组织的裂解和蛋白提取。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Solid Phase Extraction Method for Patulin in Apple Juice and Unfiltered Apple Juice
Patulin, 4-hydroxy-4H-furo[3,2c]pyran-2(6H)-one (Fig. 1 ), is alactone containing secondary metabolite of several species of Penicillium and Aspergillus. P. expansum is the most common mold producing patulin in apples, pears, and cherries
. This method is based on the conversion of the primary cytochrome P450 metabolite, 7α-hydroxycholesterol, into 7α-hydroxy-4-cholesten-3-one in a reaction catalyzed by exogenous cholesterol oxidase, followed by chromatographic separation with monitoring at 254
Therapeutic Drug Monitoring of Tamoxifen Using LC-MS/MS
) and 4-hydroxy-N-desmethyltamoxifen (endoxifen), may be clinically useful for guiding treatment decisions. Two significant barriers to tamoxifen efficacy are: (1) variability in conversion of tamoxifen into the potent antiestrogenic metabolite, endoxifen
技术资料暂无技术资料 索取技术资料
